Data collection, patient review and counselling
Data collected on patients referred to the National Renal Complement Therapeutics Centre can improve our knowledge of C3G. This includes patients referred for advice with C3G in native kidneys, and those referred for consideration of eculizumab for recurrent C3G following renal transplantation. Patients who commence eculizumab for recurrent C3G following renal transplantation will be managed on a shared care basis with the referring consultant.
All patients with C3G or MPGN (once secondary causes have been excluded) should be registered with RaDaR. A number of studies are currently available for patients with C3G (and MPGN). We recommend that patients are recruited to these studies.
The National Study of MPGN and C3G
C3G Natural History Study
Genomic England 100000 Genome Study